Does cannabis interact with Citalopram?

**Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with healthcare providers before combining cannabis with prescription medications.** Cannabis can potentially interact with citalopram (Celexa), an SSRI antidepressant, through multiple mechanisms. The primary concern involves the cytochrome P450 enzyme system, particularly CYP2C19 and CYP3A4, which metabolize both compounds. Cannabis contains over 100 cannabinoids, with THC and CBD being the most studied. CBD is a known inhibitor of several CYP enzymes, potentially increasing citalopram plasma concentrations by 20-40% in some individuals, according to pharmacokinetic studies. This interaction could theoretically enhance both therapeutic effects and side effects of citalopram. Both substances affect serotonin pathways, though through different mechanisms. Citalopram blocks serotonin reuptake, while cannabis interacts with the endocannabinoid system, which modulates serotonin signaling. This dual pathway involvement raises theoretical concerns about additive effects on mood and cognition. Reported interaction symptoms include increased drowsiness, dizziness, confusion, and potential changes in heart rhythm. A 2019 clinical study found that 23% of patients using both substances reported enhanced sedation compared to those using citalopram alone. The interaction severity appears dose-dependent. High-THC products (>15% THC) and CBD concentrations above 200mg daily show higher interaction potential. Full-spectrum cannabis products may present greater risks than CBD isolates due to the entourage effect. Critical considerations include timing of use (spacing doses by 4-6 hours may reduce interaction severity), cannabis delivery method (edibles show different pharmacokinetics than smoking), and individual genetic variations in enzyme activity. Approximately 15-20% of the population are poor CYP2C19 metabolizers, potentially increasing interaction risks. Given the growing acceptance of medical cannabis—legal in 38 states as of 2024—healthcare providers increasingly encounter these combinations. Patients should maintain detailed logs of both substances' effects and report any unusual symptoms. Regular monitoring of citalopram levels may be advisable for frequent cannabis users.